FDA issues warning letter to NeoGen over veterinary product quality defect
What happened
On October 7, 2026, the FDA issued a warning letter to NeoGen. This followed an investigation that linked the veterinary wound care product Neogen Vet HYCOAT, which was labeled sterile, to serious infections and deaths in horses. The FDA stated this incident involved at least 20 horse deaths.
From pr-inside.com
Why it matters
The FDA's action is part of enhanced U.S. food safety policies involving the FDA and NeoGen. The incident, which followed a voluntary recall of HYCOAT initiated by NeoGen in late January 2026, highlights regulatory risks associated with quality defects in veterinary medical products.
Enhanced U.S. food safety policies involve the FDA and NeoGen.
From pr-inside.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- NeoGenSpeculative
NeoGen might face reduced sales or increased costs due to regulatory action regarding its product quality.
Keep exploring
The entities involved
Related events
- FDA released a warning letter regarding device failures involving Beta Bionics, Inc.
- The FDA posted a notice regarding product contamination involving Par Pharmaceutical.
- Beta Bionics, Inc. is accused of failing to accurately describe observations made by the FDA.
- The FDA seized products from Shivay Beverages LLP on October 7, 2026, due to concerns over substandard quality.
- The FDA was tasked to review product licenses and public health warnings.